Ruxolitinib significantly enhanced apoptosis in HL and PMBCL in vitro and promoted survival in a lymphoma xenograft murine model.244 A phase 2 study (NCT01877005) of ruxolitinib in advanced relapsed or refractory HL showed poor efficacy as monotherapy (ORR 9.4% and CR 0%).245 Ruxolitinib and navitoclax, a Bcl-2/Bcl-XL inhibitor, reduced the tumor burden and prolonged survival in an ATLL xenograft murine model.246 A phase 1 study (NCT03681561) of ruxolitinib in combination with nivolumab in relapsed or refractory HL is currently recruiting patients. Here, BCL2L1 is linked to lymphoma.